<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="313ed5fe-5d2d-8cf6-e063-6294a90a15c2"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>Cefdinir Capsules, USP
 <br/>
Rx only
</title>
   <effectiveTime value="20250326"/>
   <setId root="eb354221-c476-41cb-ad87-52423f81d698"/>
   <versionNumber value="5"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="829572556"/>
            <name>REMEDYREPACK INC.</name>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="313eeee2-c14c-bed3-e063-6294a90adf32"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250326"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70518-1880" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Cefdinir</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Cefdinir</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="57237-099" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="UTY7PDF93L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARBOXYMETHYLCELLULOSE CALCIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="767IP0Y5NH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>D&amp;C RED NO. 28</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="300"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="CI0FAO63WC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CEFDINIR</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CI0FAO63WC" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CEFDINIR</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="20" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70518-1880-0" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20190219"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="14" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70518-1880-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250325"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA065434" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20190219"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48327" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="purple" xsi:type="CE">
                              <originalText>Lavender Opaque</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48334" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="turquoise" xsi:type="CE">
                              <originalText>Turquoise Opaque</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="21" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">E99</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Section_16">
               <id root="120ef4d6-8faf-f30d-e063-6294a90a3d9c"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <br/>
                  <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.</paragraph>
               </text>
               <effectiveTime value="20240223"/>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="120ef4d6-8fb0-f30d-e063-6294a90a3d9c"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <br/>
                  <paragraph>Cefdinir capsules, USP contain the active ingredient cefdinir, an extended-spectrum, semisynthetic cephalosporin, for oral administration. Chemically, cefdinir is [6R-[6α, 7β (Z)]]-7-[[(2-amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid. Cefdinir USP is a white to slightly brownish-yellow solid. It is slightly soluble in dilute hydrochloric acid and sparingly soluble in 0.1 M pH 7.0 phosphate buffer. The molecular formula is C
 
  <sub>14</sub>H
 
  <sub>13</sub>N
 
  <sub>5</sub>O
 
  <sub>5</sub>S
 
  <sub>2</sub>and the molecular weight is 395.42. Cefdinir has the structural formula shown below:

 </paragraph>
                  <br/>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Cefdinir capsules, USP contain 300 mg cefdinir USP and the following inactive ingredients: carboxymethylcellulose calcium, colloidal silicon dioxide and magnesium stearate. The empty hard gelatin capsule shells contain FD&amp;C Blue #1, D&amp;C Red #28, titanium dioxide, gelatin and sodium lauryl sulphate. The capsules are printed with edible ink containing black iron oxide and shellac.</paragraph>
               </text>
               <effectiveTime value="20240223"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cefdinir-str.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="120ef4d6-8fb1-f30d-e063-6294a90a3d9c"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20240223"/>
               <component>
                  <section ID="Section_2.1">
                     <id root="120ef4d6-8fb2-f30d-e063-6294a90a3d9c"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>Pharmacokinetics and Drug Metabolism</title>
                     <effectiveTime value="20240223"/>
                     <component>
                        <section ID="Section_2.1.1">
                           <id root="120ef4d6-8fb3-f30d-e063-6294a90a3d9c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Absorption</content>
                           </title>
                           <effectiveTime value="20240223"/>
                           <component>
                              <section ID="Section_2.1.1.1">
                                 <id root="120ef4d6-8fb4-f30d-e063-6294a90a3d9c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Oral Bioavailability</title>
                                 <text>
                                    <br/>
                                    <paragraph>Maximal plasma cefdinir concentrations occur 2 to 4 hours postdose following capsule or suspension administration. Plasma cefdinir concentrations increase with dose, but the increases are less than dose-proportional from 300 mg (7 mg/kg) to 600 mg (14 mg/kg). Following administration of suspension to healthy adults, cefdinir bioavailability is 120% relative to capsules. Estimated bioavailability of cefdinir capsules is 21% following administration of a 300 mg capsule dose, and 16% following administration of a 600 mg capsule dose. Estimated absolute bioavailability of cefdinir suspension is 25%. Cefdinir oral suspension of 250 mg/5 mL strength was shown to be bioequivalent to the 125 mg/5 mL strength in healthy adults under fasting conditions.</paragraph>
                                 </text>
                                 <effectiveTime value="20240223"/>
                              </section>
                           </component>
                           <component>
                              <section ID="Section_2.1.1.2">
                                 <id root="120ef4d6-8fb5-f30d-e063-6294a90a3d9c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Effect of Food</title>
                                 <text>
                                    <br/>
                                    <paragraph>The C
 
  <sub>max</sub>and AUC of cefdinir from the capsules are reduced by 16% and 10%, respectively, when given with a high-fat meal. In adults given the 250 mg/5 mL oral suspension with a high-fat meal, the C
 
  <sub>max</sub>and AUC of cefdinir are reduced by 44% and 33%, respectively. The magnitude of these reductions is not likely to be clinically significant because the safety and efficacy studies of oral suspension in pediatric patients were conducted without regard to food intake. Therefore, cefdinir may be taken without regard to food.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20240223"/>
                              </section>
                           </component>
                           <component>
                              <section ID="Section_2.1.1.3">
                                 <id root="120ef4d6-8fb6-f30d-e063-6294a90a3d9c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Cefdinir Capsules</title>
                                 <text>
                                    <br/>
                                    <paragraph>Cefdinir plasma concentrations and pharmacokinetic parameter values following administration of single 300 and 600 mg oral doses of cefdinir to adult subjects are presented in the following table:</paragraph>
                                    <br/>
                                    <table cellspacing="0" cellpadding="0" border="0">
                                       <caption>Mean (±SD) Plasma Cefdinir Pharmacokinetic Parameter Values Following Administration of Capsules to Adult Subjects</caption>
                                       <thead>
                                          <tr>
                                             <th styleCode="Lrule Rrule Toprule">Dose</th>
                                             <th align="center" styleCode="Lrule Rrule Toprule">C
    
     <sub>max</sub>
                                                <br/>  (mcg/mL)
   
    </th>
                                             <th align="center" styleCode="Lrule Rrule Toprule">T
    
     <sub>max</sub>
                                                <br/>  (hr)
   
    </th>
                                             <th align="center" styleCode="Lrule Rrule Toprule">AUC 
     <br/>  (mcg•hr/mL)
    </th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">   300 mg 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">1.6 
     <br/>  (0.55) 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">2.9 
     <br/>  (0.89) 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">7.05 
     <br/>  (2.17) 
     <br/>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule" valign="top">   600 mg 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">2.87 
     <br/>  (1.01) 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">3 
     <br/>  (0.66) 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">11.1 
     <br/>  (3.87) 
     <br/>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20240223"/>
                              </section>
                           </component>
                           <component>
                              <section ID="Section_2.1.1.4">
                                 <id root="120ef4d6-8fb7-f30d-e063-6294a90a3d9c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Cefdinir Suspension</title>
                                 <text>
                                    <br/>
                                    <paragraph>Cefdinir plasma concentrations and pharmacokinetic parameter values following administration of single 7 and 14 mg/kg oral doses of cefdinir to pediatric subjects (age 6 months to 12 years) are presented in the following table:</paragraph>
                                    <br/>
                                    <table cellspacing="0" cellpadding="0" border="0">
                                       <caption>Mean (±SD) Plasma Cefdinir Pharmacokinetic Parameter Values Following Administration of Suspension to Pediatric Subjects</caption>
                                       <thead>
                                          <tr>
                                             <th styleCode="Lrule Rrule Toprule">Dose</th>
                                             <th align="center" styleCode="Lrule Rrule Toprule">C
    
     <sub>max</sub>
                                                <br/>  (mcg/mL)
   
    </th>
                                             <th align="center" styleCode="Lrule Rrule Toprule">t
    
     <sub>max</sub>
                                                <br/>  (hr)
   
    </th>
                                             <th align="center" styleCode="Lrule Rrule Toprule">AUC 
     <br/>  (mcg•hr/mL)
    </th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">   7 mg/kg 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">2.3 
     <br/>  (0.65) 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">2.2 
     <br/>  (0.6) 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">8.31 
     <br/>  (2.5) 
     <br/>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule" valign="top">   14 mg/kg 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">3.86 
     <br/>  (0.62) 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">1.8 
     <br/>  (0.4) 
     <br/>
                                             </td>
                                             <td align="center" styleCode="Rrule" valign="top">13.4 
     <br/>  (2.64) 
     <br/>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20240223"/>
                              </section>
                           </component>
                           <component>
                              <section ID="Section_2.1.1.5">
                                 <id root="120ef4d6-8fb8-f30d-e063-6294a90a3d9c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Multiple Dosing</title>
                                 <text>
                                    <br/>
                                    <paragraph>Cefdinir does not accumulate in plasma following once- or twice-daily administration to subjects with normal renal function.</paragraph>
                                 </text>
                                 <effectiveTime value="20240223"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="Section_2.1.2">
                           <id root="120ef4d6-8fb9-f30d-e063-6294a90a3d9c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Distribution</content>
                           </title>
                           <text>
                              <br/>
                              <paragraph>The mean volume of distribution (Vd
 
  <sub>area</sub>) of cefdinir in adult subjects is 0.35 L/kg (±0.29); in pediatric subjects (age 6 months to 12 years), cefdinir Vd
 
  <sub>area</sub>is 0.67 L/kg (±0.38). Cefdinir is 60% to 70% bound to plasma proteins in both adult and pediatric subjects; binding is independent of concentration.

 </paragraph>
                           </text>
                           <effectiveTime value="20240223"/>
                           <component>
                              <section ID="Section_2.1.2.1">
                                 <id root="120ef4d6-8fba-f30d-e063-6294a90a3d9c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>
                                    <content styleCode="bold">Skin Blister</content>
                                 </title>
                                 <text>
                                    <br/>
                                    <paragraph>In adult subjects, median (range) maximal blister fluid cefdinir concentrations of 0.65 (0.33 to 1.1) and 1.1 (0.49 to 1.9) mcg/mL were observed 4 to 5 hours following administration of 300 and 600 mg doses, respectively. Mean (±SD) blister C
 
  <sub>max</sub>and AUC
 
  <sub>(0-∞)</sub>values were 48% (±13) and 91% (±18) of corresponding plasma values.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20240223"/>
                              </section>
                           </component>
                           <component>
                              <section ID="Section_2.1.2.2">
                                 <id root="120ef4d6-8fbb-f30d-e063-6294a90a3d9c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>
                                    <content styleCode="bold">Tonsil Tissue</content>
                                 </title>
                                 <text>
                                    <br/>
                                    <paragraph>In adult patients undergoing elective tonsillectomy, respective median tonsil tissue cefdinir concentrations 4 hours after administration of single 300 and 600 mg doses were 0.25 (0.22 to 0.46) and 0.36 (0.22 to 0.8) mcg/g. Mean tonsil tissue concentrations were 24% (±8) of corresponding plasma concentrations.</paragraph>
                                 </text>
                                 <effectiveTime value="20240223"/>
                              </section>
                           </component>
                           <component>
                              <section ID="Section_2.1.2.3">
                                 <id root="120ef4d6-8fbc-f30d-e063-6294a90a3d9c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>
                                    <content styleCode="bold">Sinus Tissue</content>
                                 </title>
                                 <text>
                                    <br/>
                                    <paragraph>In adult patients undergoing elective maxillary and ethmoid sinus surgery, respective median sinus tissue cefdinir concentrations 4 hours after administration of single 300 and 600 mg doses were &lt;0.12 (&lt;0.12 to 0.46) and 0.21 (&lt;0.12 to 2) mcg/g. Mean sinus tissue concentrations were 16% (±20) of corresponding plasma concentrations.</paragraph>
                                 </text>
                                 <effectiveTime value="20240223"/>
                              </section>
                           </component>
                           <component>
                              <section ID="Section_2.1.2.4">
                                 <id root="120ef4d6-8fbd-f30d-e063-6294a90a3d9c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>
                                    <content styleCode="bold">Lung Tissue</content>
                                 </title>
                                 <text>
                                    <br/>
                                    <paragraph>In adult patients undergoing diagnostic bronchoscopy, respective median bronchial mucosa cefdinir concentrations 4 hours after administration of single 300 and 600 mg doses were 0.78 (&lt;0.06 to 1.33) and 1.14 (&lt;0.06 to 1.92) mcg/mL, and were 31% (±18) of corresponding plasma concentrations. Respective median epithelial lining fluid concentrations were 0.29 (&lt;0.3 to 4.73) and 0.49 (&lt;0.3 to 0.59) mcg/mL, and were 35% (±83) of corresponding plasma concentrations.</paragraph>
                                 </text>
                                 <effectiveTime value="20240223"/>
                              </section>
                           </component>
                           <component>
                              <section ID="Section_2.1.2.5">
                                 <id root="120ef4d6-8fbe-f30d-e063-6294a90a3d9c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>
                                    <content styleCode="bold">Middle Ear Fluid</content>
                                 </title>
                                 <text>
                                    <br/>
                                    <paragraph>In 14 pediatric patients with acute bacterial otitis media, respective median middle ear fluid cefdinir concentrations 3 hours after administration of single 7 and 14 mg/kg doses were 0.21 (&lt;0.09 to 0.94) and 0.72 (0.14 to 1.42) mcg/mL. Mean middle ear fluid concentrations were 15% (±15) of corresponding plasma concentrations.</paragraph>
                                 </text>
                                 <effectiveTime value="20240223"/>
                              </section>
                           </component>
                           <component>
                              <section ID="Section_2.1.2.6">
                                 <id root="120ef4d6-8fbf-f30d-e063-6294a90a3d9c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>
                                    <content styleCode="bold">CSF</content>
                                 </title>
                                 <text>
                                    <br/>
                                    <paragraph>Data on cefdinir penetration into human cerebrospinal fluid are not available.</paragraph>
                                 </text>
                                 <effectiveTime value="20240223"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="Section_2.1.3">
                           <id root="120ef4d6-8fc0-f30d-e063-6294a90a3d9c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Metabolism and Excretion</content>
                           </title>
                           <text>
                              <paragraph>Cefdinir is not appreciably metabolized. Activity is primarily due to parent drug. Cefdinir is eliminated principally via renal excretion with a mean plasma elimination half-life (t
 
  <sub>½</sub>) of 1.7 (±0.6) hours. In healthy subjects with normal renal function, renal clearance is 2 (±1) mL/min/kg, and apparent oral clearance is 11.6 (±6) and 15.5 (±5.4) mL/min/kg following doses of 300 and 600 mg, respectively. Mean percent of dose recovered unchanged in the urine following 300 and 600 mg doses is 18.4% (±6.4) and 11.6% (±4.6), respectively. Cefdinir clearance is reduced in patients with renal dysfunction (see
 
  <linkHtml href="#Section_2.1.4">Special Populations</linkHtml>:
 
  <content styleCode="italics">
                                    <linkHtml href="#Section_2.1.4.1">Patients with Renal Insufficiency</linkHtml>
                                 </content>). 
  <br/>
                                 <br/>  Because renal excretion is the predominant pathway of elimination, dosage should be adjusted in patients with markedly compromised renal function or who are undergoing hemodialysis (see
 
  <content styleCode="italics">
                                    <content styleCode="bold">
                                       <linkHtml href="#Section_10">DOSAGE AND ADMINISTRATION</linkHtml>
                                    </content>
                                 </content>).

 </paragraph>
                           </text>
                           <effectiveTime value="20240223"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Section_2.1.4">
                           <id root="120ef4d6-8fc1-f30d-e063-6294a90a3d9c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Special Populations</content>
                           </title>
                           <effectiveTime value="20240223"/>
                           <component>
                              <section ID="Section_2.1.4.1">
                                 <id root="120ef4d6-8fc2-f30d-e063-6294a90a3d9c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>
                                    <content styleCode="bold">Patients with Renal Insufficiency</content>
                                 </title>
                                 <text>
                                    <br/>
                                    <paragraph>Cefdinir pharmacokinetics were investigated in 21 adult subjects with varying degrees of renal function. Decreases in cefdinir elimination rate, apparent oral clearance (CL/F), and renal clearance were approximately proportional to the reduction in creatinine clearance (CL
 
  <sub>cr</sub>). As a result, plasma cefdinir concentrations were higher and persisted longer in subjects with renal impairment than in those without renal impairment. In subjects with CL
 
  <sub>cr</sub>between 30 and 60 mL/min, C
 
  <sub>max</sub>and t
 
  <sub>½</sub>increased by approximately 2-fold and AUC by approximately 3-fold. In subjects with CL
 
  <sub>cr</sub>&lt;30 mL/min, C
 
  <sub>max</sub>increased by approximately 2-fold, t
 
  <sub>½</sub>by approximately 5-fold, and AUC by approximately 6-fold. Dosage adjustment is recommended in patients with markedly compromised renal function (creatinine clearance &lt;30 mL/min; see
 
  <content styleCode="bold">
                                          <content styleCode="bold">
                                             <linkHtml href="#Section_10">DOSAGE AND ADMINISTRATION</linkHtml>
                                          </content>
                                       </content>).

 </paragraph>
                                 </text>
                                 <effectiveTime value="20240223"/>
                              </section>
                           </component>
                           <component>
                              <section ID="Section_2.1.4.2">
                                 <id root="120ef4d6-8fc3-f30d-e063-6294a90a3d9c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>
                                    <content styleCode="bold">Hemodialysis</content>
                                 </title>
                                 <text>
                                    <br/>
                                    <paragraph>Cefdinir pharmacokinetics were studied in 8 adult subjects undergoing hemodialysis. Dialysis (4 hours duration) removed 63% of cefdinir from the body and reduced apparent elimination t
 
  <sub>½</sub>from 16 (±3.5) to 3.2 (±1.2) hours. Dosage adjustment is recommended in this patient population (see
 
  <content styleCode="bold">
                                          <content styleCode="bold">
                                             <linkHtml href="#Section_10">DOSAGE AND ADMINISTRATION</linkHtml>
                                          </content>
                                       </content>).

 </paragraph>
                                 </text>
                                 <effectiveTime value="20240223"/>
                              </section>
                           </component>
                           <component>
                              <section ID="Section_2.1.4.3">
                                 <id root="120ef4d6-8fc4-f30d-e063-6294a90a3d9c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>
                                    <content styleCode="bold">Hepatic Disease</content>
                                 </title>
                                 <text>
                                    <br/>
                                    <paragraph>Because cefdinir is predominantly renally eliminated and not appreciably metabolized, studies in patients with hepatic impairment were not conducted. It is not expected that dosage adjustment will be required in this population.</paragraph>
                                 </text>
                                 <effectiveTime value="20240223"/>
                              </section>
                           </component>
                           <component>
                              <section ID="Section_2.1.4.4">
                                 <id root="120ef4d6-8fc5-f30d-e063-6294a90a3d9c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>
                                    <content styleCode="bold">Geriatric Patients</content>
                                 </title>
                                 <text>
                                    <br/>
                                    <paragraph>The effect of age on cefdinir pharmacokinetics after a single 300 mg dose was evaluated in 32 subjects 19 to 91 years of age. Systemic exposure to cefdinir was substantially increased in older subjects (N=16), C
 
  <sub>max</sub>by 44% and AUC by 86%. This increase was due to a reduction in cefdinir clearance. The apparent volume of distribution was also reduced, thus no appreciable alterations in apparent elimination t
 
  <sub>½</sub>were observed (elderly: 2.2 ± 0.6 hours vs young: 1.8 ± 0.4 hours). Since cefdinir clearance has been shown to be primarily related to changes in renal function rather than age, elderly patients do not require dosage adjustment unless they have markedly compromised renal function (creatinine clearance &lt;30 mL/min, see
 
  <content styleCode="bold">
                                          <content styleCode="italics">
                                             <content styleCode="italics">
                                                <content styleCode="bold">
                                                   <linkHtml href="#Section_2.1.4.1">Patients with Renal Insufficiency</linkHtml>
                                                </content>
                                             </content>
                                          </content>
                                       </content>, above).

 </paragraph>
                                 </text>
                                 <effectiveTime value="20240223"/>
                              </section>
                           </component>
                           <component>
                              <section ID="Section_2.1.4.5">
                                 <id root="120ef4d6-8fc6-f30d-e063-6294a90a3d9c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Gender and Race</title>
                                 <text>
                                    <br/>
                                    <paragraph>The results of a meta-analysis of clinical pharmacokinetics (N=217) indicated no significant impact of either gender or race on cefdinir pharmacokinetics.</paragraph>
                                 </text>
                                 <effectiveTime value="20240223"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.2">
                     <id root="120ef4d6-8fc7-f30d-e063-6294a90a3d9c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Microbiology</title>
                     <text>
                        <paragraph>Mechanism of Action 
  <br/>
                           <br/>  As with other cephalosporins, bactericidal activity of cefdinir results from inhibition of cell wall synthesis. Cefdinir is stable in the presence of some, but not all, β-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins are susceptible to cefdinir. 
  <br/>
                           <br/>  Mechanism of Resistance 
  <br/>
                           <br/>  Resistance to cefdinir is primarily through hydrolysis by some β-lactamases, alteration of penicillin-binding proteins (PBPs) and decreased permeability. Cefdinir is inactive against most strains of
 
  <content styleCode="italics">Enterobacter</content>spp.,
 
  <content styleCode="italics">Pseudomonas</content>spp.,
 
  <content styleCode="italics">Enterococcus</content>spp., penicillin-resistant streptococci, and methicillin-resistant staphylococci. β-lactamase negative, ampicillin-resistant (BLNAR)
 
  <content styleCode="italics">H. influenzae</content>strains are typically non-susceptible to cefdinir. 
  <br/>
                           <br/>  Antimicrobial Activity 
  <br/>
                           <br/>  Cefdinir has been shown to be active against most strains of the following microorganisms, both
 
  <content styleCode="italics">in vitro</content>and in clinical infections as described in
 
  <content styleCode="bold">
                              <linkHtml href="#Section_3">INDICATIONS AND USAGE</linkHtml>
                           </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20240223"/>
                     <component>
                        <section ID="Section_2.2.1">
                           <id root="120ef4d6-8fc8-f30d-e063-6294a90a3d9c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">
                                 <content styleCode="italics">
                                    <content styleCode="underline">Gram-Positive Bacteria</content>
                                 </content>
                              </content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Staphylococcus aureus</content>(methicillin-susceptible strains only)

 </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Streptococcus pneumoniae</content>(penicillin-susceptible strains only)

 </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Streptococcus pyogenes</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20240223"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Section_2.2.2">
                           <id root="120ef4d6-8fc9-f30d-e063-6294a90a3d9c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="italics">
                                 <content styleCode="underline">
                                    <content styleCode="bold">Gram-Negative Bacteria</content>
                                 </content>
                              </content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Haemophilus influenzae</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Haemophilus parainfluenzae</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Moraxella catarrhalis</content>
                              </paragraph>
                              <br/>
                              <paragraph>The following
 
  <content styleCode="italics">in vitro</content>data are available, but their clinical significance is unknown. 
  <br/>
                                 <br/>  Cefdinir exhibits
 
  <content styleCode="italics">in vitro</content>minimum inhibitory concentrations (MICs) of 1 mcg/mL or less against (≥90%) strains of the following microorganisms; however, the safety and effectiveness of cefdinir in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled clinical trials.

 </paragraph>
                           </text>
                           <effectiveTime value="20240223"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Section_2.2.3">
                           <id root="120ef4d6-8fca-f30d-e063-6294a90a3d9c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="italics">
                                 <content styleCode="underline">
                                    <content styleCode="bold">Gram-Positive Bacteria</content>
                                 </content>
                              </content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Staphylococcus epidermidis</content>(methicillin-susceptible strains only)

 </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Streptococcus agalactiae</content>
                              </paragraph>
                              <paragraph>Viridans group streptococci</paragraph>
                           </text>
                           <effectiveTime value="20240223"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Section_2.2.4">
                           <id root="120ef4d6-8fcb-f30d-e063-6294a90a3d9c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">
                                 <content styleCode="italics">
                                    <content styleCode="bold">Gram-Negative Bacteria</content>
                                 </content>
                              </content>
                           </title>
                           <text>
                              <br/>
                              <paragraph>
                                 <content styleCode="italics">Citrobacter koseri 
   <br/>  Escherichia coli 
   <br/>  Klebsiella pneumoniae 
   <br/>  Proteus mirabilis
  </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20240223"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.3">
                     <id root="120ef4d6-8fcc-f30d-e063-6294a90a3d9c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="underline">Susceptibility Testing</content>
                     </title>
                     <text>
                        <paragraph>For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.</paragraph>
                     </text>
                     <effectiveTime value="20240223"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="120ef4d6-8fcd-f30d-e063-6294a90a3d9c"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <br/>
                  <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. 
  <br/>
                     <br/>  Cefdinir capsules, USP are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below.
 </paragraph>
               </text>
               <effectiveTime value="20240223"/>
               <component>
                  <section ID="Section_3.1">
                     <id root="120ef4d6-8fce-f30d-e063-6294a90a3d9c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Adults and Adolescents</title>
                     <text>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Community-Acquired Pneumonia</content>caused by
 
  <content styleCode="italics">Haemophilus influenzae</content>(including β-lactamase producing strains),
 
  <content styleCode="italics">Haemophilus parainfluenzae</content>(including β-lactamase producing strains),
 
  <content styleCode="italics">Streptococcus pneumoniae</content>(penicillin-susceptible strains only), and
 
  <content styleCode="italics">Moraxella catarrhalis</content>(including β-lactamase producing strains) (see
 
  <content styleCode="bold">
                              <content styleCode="bold">
                                 <linkHtml href="#Section_13">CLINICAL STUDIES</linkHtml>
                              </content>
                           </content>). 
  <br/>
                           <br/>
                           <content styleCode="bold">Acute Exacerbations of Chronic Bronchitis</content>caused by
 
  <content styleCode="italics">Haemophilus influenzae</content>(including β-lactamase producing strains),
 
  <content styleCode="italics">Haemophilus parainfluenzae</content>(including β-lactamase producing strains),
 
  <content styleCode="italics">Streptococcus pneumoniae</content>(penicillin-susceptible strains only), and
 
  <content styleCode="italics">Moraxella catarrhalis</content>(including β-lactamase producing strains). 
  <br/>
                           <br/>
                           <content styleCode="bold">Acute Maxillary Sinusitis</content>caused by
 
  <content styleCode="italics">Haemophilus influenzae</content>(including β-lactamase producing strains),
 
  <content styleCode="italics">Streptococcus pneumoniae</content>(penicillin-susceptible strains only), and
 
  <content styleCode="italics">Moraxella catarrhalis</content>(including β-lactamase producing strains). 
  <br/>
                           <br/>
                           <content styleCode="bold">NOTE:</content>For information on use in pediatric patients, see
 
  <content styleCode="bold">
                              <content styleCode="bold">
                                 <linkHtml href="#Section_6.10">Pediatric Use</linkHtml>
                              </content> 
 
  </content>and
 
  <content styleCode="bold">
                              <content styleCode="bold">
                                 <linkHtml href="#Section_10">DOSAGE AND ADMINISTRATION</linkHtml>
                              </content>
                           </content>.
 
  <content styleCode="bold">
                              <br/>
                              <br/>  Pharyngitis/Tonsillitis
  </content>caused by
 
  <content styleCode="italics">Streptococcus pyogenes</content>(see
 
  <content styleCode="bold">
                              <content styleCode="bold">
                                 <linkHtml href="#Section_13">CLINICAL STUDIES</linkHtml>
                              </content>
                           </content>). 
  <br/>
                           <br/>
                           <content styleCode="bold">NOTE:</content>Cefdinir is effective in the eradication of
 
  <content styleCode="italics">S. pyogenes</content>from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following
 
  <content styleCode="italics">S. pyogenes</content>pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. 
  <br/>
                           <content styleCode="bold">
                              <br/>  Uncomplicated Skin and Skin Structure Infections
  </content>caused by
 
  <content styleCode="italics">Staphylococcus aureus</content>(including β-lactamase producing strains) and
 
  <content styleCode="italics">Streptococcus pyogenes</content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20240223"/>
                  </section>
               </component>
               <component>
                  <section ID="section_3.2">
                     <id root="120ef4d6-8fcf-f30d-e063-6294a90a3d9c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Pediatric Patients</title>
                     <text>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Acute Bacterial Otitis Media</content>caused by
 
  <content styleCode="italics">Haemophilus influenzae</content>(including β-lactamase producing strains),
 
  <content styleCode="italics">Streptococcus pneumoniae</content>(penicillin-susceptible strains only), and
 
  <content styleCode="italics">Moraxella catarrhalis</content>(including β-lactamase producing strains).
 
  <content styleCode="bold">
                              <br/>
                              <br/>  Pharyngitis/Tonsillitis
  </content>caused by
 
  <content styleCode="italics">Streptococcus pyogenes</content>(see
 
  <content styleCode="bold">
                              <content styleCode="bold">
                                 <linkHtml href="#Section_13">CLINICAL STUDIES</linkHtml>
                              </content>
                           </content>).
 
  <content styleCode="bold">
                              <br/>
                              <br/>  NOTE:
  </content>Cefdinir is effective in the eradication of
 
  <content styleCode="italics">S. pyogenes</content>from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following
 
  <content styleCode="italics">S. pyogenes</content>pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. 
  <br/>
                           <content styleCode="bold">
                              <br/>  Uncomplicated Skin and Skin Structure Infections
  </content>caused by
 
  <content styleCode="italics">Staphylococcus aureus</content>(including β-lactamase producing strains) and
 
  <content styleCode="italics">Streptococcus pyogenes</content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20240223"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="120ef4d6-8fd0-f30d-e063-6294a90a3d9c"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <br/>
                  <paragraph>Cefdinir capsules are contraindicated in patients with known allergy to the cephalosporin class of antibiotics.</paragraph>
               </text>
               <effectiveTime value="20240223"/>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="120ef4d6-8fd1-f30d-e063-6294a90a3d9c"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">BEFORE THERAPY WITH CEFDINIR IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFDINIR, OTHER CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF CEFDINIR IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-HYPERSENSITIVITY AMONG β-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. IF AN ALLERGIC REACTION TO CEFDINIR OCCURS, THE DRUG SHOULD BE DISCONTINUED. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. 
   <br/>
                     </content>
                     <br/>
                     <content styleCode="italics">Clostridium difficile</content>associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including cefdinir, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of
 
  <content styleCode="italics">C. difficile</content>. 
  <br/>
                     <br/>
                     <content styleCode="italics">C. difficile</content>produces toxins A and B which contribute to the development of CDAD.  Hypertoxin producing strains of
 
  <content styleCode="italics">C. difficile</content>cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. 
  <br/>
                     <br/>  If CDAD is suspected or confirmed, ongoing antibacterial use not directed against
 
  <content styleCode="italics">C</content>.
 
  <content styleCode="italics">difficile</content>may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of
 
  <content styleCode="italics">C. difficile</content>, and surgical evaluation should be instituted as clinically indicated.

 </paragraph>
               </text>
               <effectiveTime value="20240223"/>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="120ef4d6-8fd2-f30d-e063-6294a90a3d9c"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20240223"/>
               <component>
                  <section ID="Section_6.1">
                     <id root="120ef4d6-8fd3-f30d-e063-6294a90a3d9c"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General</title>
                     <text>
                        <br/>
                        <paragraph>Prescribing cefdinir in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. 
  <br/>
                           <br/>  As with other broad-spectrum antibiotics, prolonged treatment may result in the possible emergence and overgrowth of resistant organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate alternative therapy should be administered. 
  <br/>
                           <br/>  Cefdinir, as with other broad-spectrum antimicrobials (antibiotics), should be prescribed with caution in individuals with a history of colitis. 
  <br/>
                           <br/>  In patients with transient or persistent renal insufficiency (creatinine clearance &lt;30 mL/min), the total daily dose of cefdinir should be reduced because high and prolonged plasma concentrations of cefdinir can result following recommended doses (see
 
  <content styleCode="bold">
                              <content styleCode="bold">
                                 <linkHtml href="#Section_10">DOSAGE AND ADMINISTRATION</linkHtml>
                              </content>
                           </content>).

 </paragraph>
                     </text>
                     <effectiveTime value="20240223"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.2">
                     <id root="120ef4d6-8fd4-f30d-e063-6294a90a3d9c"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for Patients</title>
                     <text>
                        <br/>
                        <paragraph>Patients should be counseled that antibacterial drugs including cefdinir should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When cefdinir is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by cefdinir or other antibacterial drugs in the future. 
  <br/>
                           <br/>  Antacids containing magnesium or aluminum interfere with the absorption of cefdinir. If this type of antacid is required during cefdinir therapy, cefdinir should be taken at least 2 hours before or after the antacid. 
  <br/>
                           <br/>  Iron supplements, including multivitamins that contain iron, interfere with the absorption of cefdinir. If iron supplements are required during cefdinir therapy, cefdinir should be taken at least 2 hours before or after the supplement. 
  <br/>
                           <br/>  Iron-fortified infant formula does not significantly interfere with the absorption of cefdinir. 
  <br/>
                           <br/>  Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued.  Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.
 </paragraph>
                        <paragraph>Repackaged By / Distributed By: RemedyRepack Inc.</paragraph>
                        <paragraph>625 Kolter Drive, Indiana, PA 15701</paragraph>
                        <paragraph>(724) 465-8762</paragraph>
                     </text>
                     <effectiveTime value="20240223"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.4">
                     <id root="120ef4d6-8fd5-f30d-e063-6294a90a3d9c"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>Drug Interactions</title>
                     <effectiveTime value="20240223"/>
                     <component>
                        <section ID="Section_6.4.1">
                           <id root="120ef4d6-8fd6-f30d-e063-6294a90a3d9c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">
                                 <content styleCode="italics">Antacids</content>
                              </content>(aluminum- or magnesium-containing)
</title>
                           <text>
                              <paragraph>Concomitant administration of 300 mg cefdinir capsules with 30 mL Maalox
 
  <sup>®</sup>TC suspension reduces the rate (C
 
  <sub>max</sub>) and extent (AUC) of absorption by approximately 40%. Time to reach C
 
  <sub>max</sub>is also prolonged by 1 hour. There are no significant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdinir. If antacids are required during cefdinir therapy, cefdinir should be taken at least 2 hours before or after the antacid.

 </paragraph>
                           </text>
                           <effectiveTime value="20240223"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Section_6.4.2">
                           <id root="120ef4d6-8fd7-f30d-e063-6294a90a3d9c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">
                                 <content styleCode="italics">Probenecid</content>
                              </content>
                           </title>
                           <text>
                              <br/>
                              <paragraph>As with other β-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in AUC, a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination t
 
  <sub>½</sub>.

 </paragraph>
                           </text>
                           <effectiveTime value="20240223"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Section_6.4.3">
                           <id root="120ef4d6-8fd8-f30d-e063-6294a90a3d9c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">
                                 <content styleCode="italics">Iron Supplements and Foods Fortified With Iron</content>
                              </content>
                           </title>
                           <text>
                              <br/>
                              <paragraph>Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO
 
  <sub>4</sub>) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively. If iron supplements are required during cefdinir therapy, cefdinir should be taken at least 2 hours before or after the supplement. 
  <br/>
                                 <br/>  The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied. 
  <br/>
                                 <br/>  Concomitantly administered iron-fortified infant formula (2.2 mg elemental iron/6 oz) has no significant effect on cefdinir pharmacokinetics. 
  <br/>
                                 <br/>  There have been reports of reddish stools in patients receiving cefdinir. In many cases, patients were also receiving iron-containing products. The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.

 </paragraph>
                           </text>
                           <effectiveTime value="20240223"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.5">
                     <id root="120ef4d6-8fd9-f30d-e063-6294a90a3d9c"/>
                     <code code="34074-5" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG &amp; OR LABORATORY TEST INTERACTIONS SECTION"/>
                     <title>Drug/Laboratory Test Interactions</title>
                     <text>
                        <br/>
                        <paragraph>A false-positive reaction for ketones in the urine may occur with tests using nitroprusside, but not with those using nitroferricyanide. The administration of cefdinir may result in a false-positive reaction for glucose in urine using Clinitest
 
  <sup>®</sup>, Benedict’s solution, or Fehling’s solution. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix
 
  <sup>®</sup>or Tes-Tape
 
  <sup>®</sup>) be used. Cephalosporins are known to occasionally induce a positive direct Coombs’ test.

 </paragraph>
                     </text>
                     <effectiveTime value="20240223"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.6">
                     <id root="120ef4d6-8fda-f30d-e063-6294a90a3d9c"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <br/>
                        <paragraph>The carcinogenic potential of cefdinir has not been evaluated. No mutagenic effects were seen in the bacterial reverse mutation assay (Ames) or point mutation assay at the hypoxanthine-guanine phosphoribosyltransferase locus (HGPRT) in V79 Chinese hamster lung cells. No clastogenic effects were observed
 
  <content styleCode="italics">in vitro</content>in the structural chromosome aberration assay in V79 Chinese hamster lung cells or
 
  <content styleCode="italics">in vivo</content>in the micronucleus assay in mouse bone marrow. In rats, fertility and reproductive performance were not affected by cefdinir at oral doses up to 1000 mg/kg/day (70 times the human dose based on mg/kg/day, 11 times based on mg/m
 
  <sup>2</sup>/day).

 </paragraph>
                     </text>
                     <effectiveTime value="20240223"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.7">
                     <id root="120ef4d6-8fdb-f30d-e063-6294a90a3d9c"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy</title>
                     <effectiveTime value="20240223"/>
                     <component>
                        <section ID="Section_6.7.1">
                           <id root="120ef4d6-8fdc-f30d-e063-6294a90a3d9c"/>
                           <code code="34077-8" codeSystem="2.16.840.1.113883.6.1" displayName="TERATOGENIC EFFECTS SECTION"/>
                           <title>
                              <content styleCode="bold">Teratogenic Effects</content>
                           </title>
                           <text>
                              <br/>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Pregnancy Category B</content>
                                 </content>
                                 <br/>
                                 <br/>  Cefdinir was not teratogenic in rats at oral doses up to 1000 mg/kg/day (70 times the human dose based on mg/kg/day, 11 times based on mg/m
 
  <sup>2</sup>/day) or in rabbits at oral doses up to 10 mg/kg/day (0.7 times the human dose based on mg/kg/day, 0.23 times based on mg/m
 
  <sup>2</sup>/day). Maternal toxicity (decreased body weight gain) was observed in rabbits at the maximum tolerated dose of 10 mg/kg/day without adverse effects on offspring. Decreased body weight occurred in rat fetuses at ≥100 mg/kg/day, and in rat offspring at ≥32 mg/kg/day. No effects were observed on maternal reproductive parameters or offspring survival, development, behavior, or reproductive function. 
  <br/>
                                 <br/>  There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

 </paragraph>
                           </text>
                           <effectiveTime value="20240223"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.8">
                     <id root="120ef4d6-8fdd-f30d-e063-6294a90a3d9c"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>Labor and Delivery</title>
                     <text>
                        <br/>
                        <paragraph>Cefdinir has not been studied for use during labor and delivery.</paragraph>
                     </text>
                     <effectiveTime value="20240223"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.9">
                     <id root="120ef4d6-8fde-f30d-e063-6294a90a3d9c"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <br/>
                        <paragraph>Following administration of single 600 mg doses, cefdinir was not detected in human breast milk.</paragraph>
                     </text>
                     <effectiveTime value="20240223"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.10">
                     <id root="120ef4d6-8fdf-f30d-e063-6294a90a3d9c"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <br/>
                        <paragraph>Safety and efficacy in neonates and infants less than 6 months of age have not been established. Use of cefdinir for the treatment of acute maxillary sinusitis in pediatric patients (age 6 months through 12 years) is supported by evidence from adequate and well-controlled studies in adults and adolescents, the similar pathophysiology of acute sinusitis in adult and pediatric patients, and comparative pharmacokinetic data in the pediatric population.</paragraph>
                     </text>
                     <effectiveTime value="20240223"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.11">
                     <id root="120ef4d6-8fe0-f30d-e063-6294a90a3d9c"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>Geriatric Use</title>
                     <text>
                        <br/>
                        <paragraph>Efficacy is comparable in geriatric patients and younger adults. While cefdinir has been well-tolerated in all age groups, in clinical trials geriatric patients experienced a lower rate of adverse events, including diarrhea, than younger adults. Dose adjustment in elderly patients is not necessary unless renal function is markedly compromised (see
 
  <content styleCode="bold">
                              <content styleCode="bold">
                                 <linkHtml href="#Section_10">DOSAGE AND ADMINISTRATION</linkHtml>
                              </content>
                           </content>).

 </paragraph>
                     </text>
                     <effectiveTime value="20240223"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_7">
               <id root="120ef4d6-8fe1-f30d-e063-6294a90a3d9c"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE EVENTS</title>
               <effectiveTime value="20240223"/>
               <component>
                  <section ID="Section_7.1">
                     <id root="120ef4d6-8fe2-f30d-e063-6294a90a3d9c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Clinical Trials - Cefdinir Capsules (Adult and Adolescent Patients)</title>
                     <text>
                        <paragraph>In clinical trials, 5093 adult and adolescent patients (3841 U.S. and 1252 non-U.S.) were treated with the recommended dose of cefdinir capsules (600 mg/day). Most adverse events were mild and self-limiting. No deaths or permanent disabilities were attributed to cefdinir. One hundred forty-seven of 5093 (3%) patients discontinued medication due to adverse events thought by the investigators to be possibly, probably, or definitely associated with cefdinir therapy. The discontinuations were primarily for gastrointestinal disturbances, usually diarrhea or nausea. Nineteen of 5093 (0.4%) patients were discontinued due to rash thought related to cefdinir administration.</paragraph>
                        <br/>
                        <paragraph>In the U.S., the following adverse events were thought by investigators to be possibly, probably, or definitely related to cefdinir capsules in multiple-dose clinical trials (N = 3841 cefdinir-treated patients):</paragraph>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <caption>ADVERSE EVENTS ASSOCIATED WITH CEFDINIR CAPSULES U.S. TRIALS IN ADULT AND ADOLESCENT PATIENTS (N = 3841)
  
   <sup>a</sup>
                           </caption>
                           <col width="43.62%"/>
                           <col width="31.04%"/>
                           <col width="25.34%"/>
                           <tfoot>
                              <tr>
                                 <td colspan="2"> 
    
     <sup>a</sup>1733 males, 2108 females
   
    </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td rowspan="6" styleCode="Lrule Rrule" valign="top">Incidence ≥1% 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">Diarrhea 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">15% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Vaginal moniliasis 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">4% of women 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Nausea 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">3% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Headache 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">2% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Abdominal pain 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">1% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Vaginitis 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">1% of women 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td rowspan="15" styleCode="Lrule Rrule" valign="top">Incidence &lt;1% but &gt;0.1% 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">Rash 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0.9% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Dyspepsia 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0.7% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Flatulence 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0.7% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Vomiting 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0.7% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Abnormal stools 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0.3% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Anorexia 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0.3% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Constipation 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0.3% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Dizziness 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0.3% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Dry mouth 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0.3% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Asthenia 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0.2% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Insomnia 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0.2% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Leukorrhea 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0.2% of women 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Moniliasis 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0.2% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Pruritus 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0.2% 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">Somnolence 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">0.2% 
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>The following laboratory value changes of possible clinical significance, irrespective of relationship to therapy with cefdinir, were seen during clinical trials conducted in the U.S.:</paragraph>
                        <br/>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <caption>LABORATORY VALUE CHANGES OBSERVED WITH CEFDINIR CAPSULES U.S. TRIALS IN ADULT AND ADOLESCENT PATIENTS (N = 3841)</caption>
                           <col width="29.3%"/>
                           <col width="53.86%"/>
                           <col width="16.84%"/>
                           <tfoot>
                              <tr>
                                 <td colspan="2">
                                    <sup>a</sup>N &lt;3841 for these parameters
   
    </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td rowspan="5" styleCode="Lrule Rrule" valign="top">Incidence ≥1% 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">↑Urine leukocytes 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">2% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">↑Urine protein 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">2% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">↑Gamma-glutamyltransferase
    
     <sup>a</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">1% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">↓Lymphocytes, ↑Lymphocytes 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">1%, 0.2% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">↑Microhematuria 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">1% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td rowspan="18" styleCode="Lrule Rrule" valign="top">Incidence &lt;1% but &gt;0.1% 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">↑Glucose
    
     <sup>a</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.9% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">↑Urine glucose 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.9% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">↑White blood cells, ↓White blood cells 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.9%, 0.7% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">↑Alanine aminotransferase (ALT) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.7% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">↑Eosinophils 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.7% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">↑Urine specific gravity, ↓Urine specific gravity
    
     <sup>a</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.6%, 0.2% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">↓Bicarbonate
    
     <sup>a</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.6% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">↑Phosphorus, ↓Phosphorus
    
     <sup>a</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.6%, 0.3% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">↑Aspartate aminotransferase (AST) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.4% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">↑Alkaline phosphatase 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.3% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">↑Blood urea nitrogen (BUN) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.3% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">↓Hemoglobin 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.3% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">↑Polymorphonuclear neutrophils (PMNs),  ↓PMNs 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.3%, 0.2% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">↑Bilirubin 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.2% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">↑Lactate dehydrogenase
    
     <sup>a</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.2% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">↑Platelets 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.2% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">↑Potassium
    
     <sup>a</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.2% 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">↑Urine pH
    
     <sup>a</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.2% 
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                     </text>
                     <effectiveTime value="20240223"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.2">
                     <id root="120ef4d6-8fe3-f30d-e063-6294a90a3d9c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Clinical Trials - Cefdinir for Oral Suspension (Pediatric Patients)</title>
                     <text>
                        <br/>
                        <paragraph>In clinical trials, 2289 pediatric patients (1783 U.S. and 506 non-U.S.) were treated with the recommended dose of cefdinir suspension (14 mg/kg/day). Most adverse events were mild and self-limiting. No deaths or permanent disabilities were attributed to cefdinir. Forty of 2289 (2%) patients discontinued medication due to adverse events considered by the investigators to be possibly, probably, or definitely associated with cefdinir therapy. Discontinuations were primarily for gastrointestinal disturbances, usually diarrhea. Five of 2289 (0.2%) patients were discontinued due to rash thought related to cefdinir administration. 
  <br/>
                           <br/>  In the U.S., the following adverse events were thought by investigators to be possibly, probably, or definitely related to cefdinir suspension in multiple-dose clinical trials (N = 1783 cefdinir-treated patients):
 </paragraph>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0" width="540">
                           <col width="40%"/>
                           <col width="31.1111111111111%"/>
                           <col width="28.8888888888889%"/>
                           <thead>
                              <tr>
                                 <th colspan="3" align="center" styleCode="Lrule Rrule Toprule">   ADVERSE EVENTS ASSOCIATED WITH CEFDINIR SUSPENSION    
     <br/>  U.S. TRIALS IN PEDIATRIC PATIENTS 
     <br/>  (N = 1783)
    
     <sup>a</sup>
                                 </th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="3">
                                    <sup>a</sup>977 males, 806 females 
     <br/>
                                    <sup>b</sup>Laboratory changes were occasionally reported as adverse events.
    
     <content styleCode="bold"/>
                                    <br/>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td rowspan="3" styleCode="Lrule Rrule" valign="top">   Incidence ≥ 1% 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">   Diarrhea 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">8% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Rash 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">3% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Vomiting 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">1% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td rowspan="11" styleCode="Lrule Rrule" valign="top">   Incidence &lt;1% but &gt;0.1%    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">   Cutaneous moniliasis 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.9% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Abdominal pain 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.8% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Leukopenia
    
     <sup>b</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.3% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Vaginal moniliasis 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">   0.3% of girls    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Vaginitis 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">   0.3% of girls    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Abnormal stools 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.2% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Dyspepsia 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.2% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Hyperkinesia 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.2% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Increased AST
    
     <sup>b</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.2% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   Maculopapular rash 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.2% 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">   Nausea 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.2% 
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>NOTE: In both cefdinir- and control-treated patients, rates of diarrhea and rash were higher in the youngest pediatric patients. The incidence of diarrhea in cefdinir-treated patients ≤2 years of age was 17% (95/557) compared with 4% (51/1226) in those &gt;2 years old. The incidence of rash (primarily diaper rash in the younger patients) was 8% (43/557) in patients ≤2 years of age compared with 1% (8/1226) in those &gt;2 years old. 
  <br/>
                           <br/>  The following laboratory value changes of possible clinical significance, irrespective of relationship to therapy with cefdinir, were seen during clinical trials conducted in the U.S.:
 </paragraph>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0" width="590.52">
                           <col width="37.8378378378378%"/>
                           <col width="37.8378378378378%"/>
                           <col width="24.3243243243243%"/>
                           <thead>
                              <tr>
                                 <th colspan="3" align="center" styleCode="Lrule Rrule Toprule">LABORATORY VALUE CHANGES OF POSSIBLE CLINICAL 
     <br/>  SIGNIFICANCE OBSERVED WITH CEFDINIR SUSPENSION 
     <br/>  U.S. TRIALS IN PEDIATRIC PATIENTS 
     <br/>  (N = 1783)
    </th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="3">
                                    <sup>a</sup>N = 1387 for these parameters
    
     <content styleCode="bold"> </content>
                                    <br/>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td rowspan="8" styleCode="Lrule Rrule" valign="top">   Incidence ≥1% 
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">   ↑Lymphocytes, ↓Lymphocytes 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">   2%, 0.8%    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   ↑Alkaline phosphatase 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">1% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   ↓Bicarbonate
    
     <sup>a</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">1% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   ↑Eosinophils 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">1% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   ↑Lactate dehydrogenase 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">1% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   ↑Platelets 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">1% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   ↑PMNs, ↓PMNs 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">1%, 1% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   ↑Urine protein 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">1% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td rowspan="11" styleCode="Lrule Rrule" valign="top">   Incidence &lt;1% but &gt;0.1%    
     <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">   ↑Phosphorus, ↓Phosphorus 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">   0.9%, 0.4%    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   ↑Urine pH 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.8% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   ↓White blood cells, ↑White blood cells 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">   0.7%, 0.3%    
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   ↓Calcium
    
     <sup>a</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.5% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   ↓Hemoglobin 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.5% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   ↑Urine leukocytes 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.5% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   ↑Monocytes 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.4% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   ↑AST 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.3% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   ↑Potassium
    
     <sup>a</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.3% 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">   ↑Urine specific gravity, ↓Urine specific gravity    
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">   0.3%, 0.1%    
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">   ↓Hematocrit
    
     <sup>a</sup>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">0.2% 
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240223"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.3">
                     <id root="120ef4d6-8fe4-f30d-e063-6294a90a3d9c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Postmarketing Experience</title>
                     <text>
                        <br/>
                        <paragraph>The following adverse experiences and altered laboratory tests, regardless of their relationship to cefdinir, have been reported during extensive postmarketing experience, beginning with approval in Japan in 1991: shock, anaphylaxis with rare cases of fatality, facial and laryngeal edema, feeling of suffocation, serum sickness-like reactions, conjunctivitis, stomatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, erythema multiforme, erythema nodosum, acute hepatitis, cholestasis, fulminant hepatitis, hepatic failure, jaundice, increased amylase, acute enterocolitis, bloody diarrhea, hemorrhagic colitis, melena, pseudomembranous colitis, pancytopenia, granulocytopenia, leukopenia, thrombocytopenia, idiopathic thrombocytopenic purpura, hemolytic anemia, acute respiratory failure, asthmatic attack, drug-induced pneumonia, eosinophilic pneumonia, idiopathic interstitial pneumonia, fever, acute renal failure, nephropathy, bleeding tendency, coagulation disorder, disseminated intravascular coagulation, upper GI bleed, peptic ulcer, ileus, loss of consciousness, allergic vasculitis, possible cefdinir-diclofenac interaction, cardiac failure, chest pain, myocardial infarction, hypertension, involuntary movements, and rhabdomyolysis.</paragraph>
                     </text>
                     <effectiveTime value="20240223"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.4">
                     <id root="120ef4d6-8fe5-f30d-e063-6294a90a3d9c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Cephalosporin Class Adverse Events</title>
                     <text>
                        <br/>
                        <paragraph>The following adverse events and altered laboratory tests have been reported for cephalosporin-class antibiotics in general: 
  <br/>
                           <br/>  Allergic reactions, anaphylaxis, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, renal dysfunction, toxic nephropathy, hepatic dysfunction including cholestasis, aplastic anemia, hemolytic anemia, hemorrhage, false-positive test for urinary glucose, neutropenia, pancytopenia, and agranulocytosis. Pseudomembranous colitis symptoms may begin during or after antibiotic treatment (see
 
  <content styleCode="bold">
                              <content styleCode="bold">
                                 <linkHtml href="#Section_5">WARNINGS</linkHtml>
                              </content>
                           </content>). 
  <br/>
                           <br/>  Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced (see
 
  <content styleCode="bold">
                              <content styleCode="bold">
                                 <linkHtml href="#Section_10">DOSAGE AND ADMINISTRATION</linkHtml>
                              </content>
                           </content>and
 
  <content styleCode="bold">
                              <content styleCode="bold">
                                 <linkHtml href="#Section_9">OVERDOSAGE</linkHtml>
                              </content>
                           </content>). If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.

 </paragraph>
                     </text>
                     <effectiveTime value="20240223"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_9">
               <id root="120ef4d6-8fe6-f30d-e063-6294a90a3d9c"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <br/>
                  <paragraph>Information on cefdinir overdosage in humans is not available. In acute rodent toxicity studies, a single oral 5600 mg/kg dose produced no adverse effects. Toxic signs and symptoms following overdosage with other β-lactam antibiotics have included nausea, vomiting, epigastric distress, diarrhea, and convulsions. Hemodialysis removes cefdinir from the body. This may be useful in the event of a serious toxic reaction from overdosage, particularly if renal function is compromised.</paragraph>
               </text>
               <effectiveTime value="20240223"/>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="120ef4d6-8fe7-f30d-e063-6294a90a3d9c"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <br/>
                  <paragraph>(see
 
  <content styleCode="bold">
                        <content styleCode="bold">
                           <linkHtml href="#Section_3">INDICATIONS AND USAGE</linkHtml>
                        </content> 
 
  </content>for Indicated Pathogens) 
  <br/>
                     <br/>  The recommended dosage and duration of treatment for infections in adults and adolescents are described in the following chart; the total daily dose for all infections is 600 mg. Once-daily dosing for 10 days is as effective as BID dosing. Once-daily dosing has not been studied in pneumonia or skin infections; therefore, cefdinir capsules should be administered twice daily in these infections. Cefdinir capsules may be taken without regard to meals.

 </paragraph>
                  <br/>
                  <table cellspacing="0" cellpadding="0" border="0">
                     <caption>Adults and Adolescents (Age 13 Years and Older)</caption>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Rrule Toprule">Type of Infection</th>
                           <th align="center" styleCode="Lrule Rrule Toprule">Dosage</th>
                           <th align="center" styleCode="Lrule Rrule Toprule">Duration</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">   Community-Acquired Pneumonia 
     <br/>
                           </td>
                           <td align="center" styleCode="Rrule" valign="top">300 mg q12h 
     <br/>
                           </td>
                           <td align="center" styleCode="Rrule" valign="top">10 days 
     <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">   Acute Exacerbations of Chronic Bronchitis 
     <br/>    
     <br/>    
     <br/>
                           </td>
                           <td align="center" styleCode="Rrule" valign="top">300 mg q12h 
     <br/>  or 
     <br/>  600 mg q24h 
     <br/>
                           </td>
                           <td align="center" styleCode="Rrule" valign="top">5 to 10 days 
     <br/>  10 days 
     <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">   Acute Maxillary Sinusitis 
     <br/>    
     <br/>    
     <br/>
                           </td>
                           <td align="center" styleCode="Rrule" valign="top">300 mg q12h 
     <br/>  or 
     <br/>  600 mg q24h 
     <br/>
                           </td>
                           <td align="center" styleCode="Rrule" valign="top">10 days 
     <br/>  10 days 
     <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">   Pharyngitis/Tonsillitis 
     <br/>    
     <br/>    
     <br/>
                           </td>
                           <td align="center" styleCode="Rrule" valign="top">300 mg q12h 
     <br/>  or 
     <br/>  600 mg q24h 
     <br/>
                           </td>
                           <td align="center" styleCode="Rrule" valign="top">5 to 10 days 
     <br/>  10 days 
     <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" valign="top">   Uncomplicated Skin and Skin Structure Infections 
     <br/>
                           </td>
                           <td align="center" styleCode="Rrule" valign="top">300 mg q12h 
     <br/>
                           </td>
                           <td align="center" styleCode="Rrule" valign="top">10 days 
     <br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20240223"/>
               <component>
                  <section ID="Section_10.1">
                     <id root="120ef4d6-8fe8-f30d-e063-6294a90a3d9c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Patients With Renal Insufficiency</title>
                     <text>
                        <br/>
                        <paragraph>For adult patients with creatinine clearance &lt;30 mL/min, the dose of cefdinir should be 300 mg given once daily. 
  <br/>
                           <br/>  Creatinine clearance is difficult to measure in outpatients. However, the following formula may be used to estimate creatinine clearance (CL
 
  <sub>cr</sub>) in adult patients. For estimates to be valid, serum creatinine levels should reflect steady-state levels of renal function. 
  <br/>
                           <br/>  Males:              CL
 
  <sub>cr</sub>=  
 
  <content styleCode="underline">    </content>
                           <content styleCode="underline">(weight) (140 – age)    </content>     
  <br/>                                         (72) (serum creatinine) 
  <br/>
                           <br/>  Females:           CL
 
  <sub>cr</sub>= 0.85 x above value 
  <br/>
                           <br/>  where creatinine clearance is in mL/min, age is in years, weight is in kilograms, and serum creatinine is in mg/dL.
 
  <sup>1</sup>
                           <br/>
                           <br/>  The following formula may be used to estimate creatinine clearance in pediatric patients: 
  <br/>
                           <br/>  CL
 
  <sub>cr</sub>=      K  x 
 
  <content styleCode="underline"> body length or height </content>
                           <br/>                              serum creatinine 
  <br/>
                           <br/>  where K=0.55 for pediatric patients older than 1 year
 
  <sup>2</sup>and 0.45 for infants (up to 1 year)
 
  <sup>3</sup>. 
  <br/>
                           <br/>  In the above equation, creatinine clearance is in mL/min/1.73 m
 
  <sup>2</sup>, body length or height is in centimeters, and serum creatinine is in mg/dL. 
  <br/>
                           <br/>  For pediatric patients with a creatinine clearance of &lt;30 mL/min/1.73 m
 
  <sup>2</sup>, the dose of cefdinir should be 7 mg/kg (up to 300 mg) given once daily.

 </paragraph>
                     </text>
                     <effectiveTime value="20240223"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_10.2">
                     <id root="120ef4d6-8fe9-f30d-e063-6294a90a3d9c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Patients on Hemodialysis</title>
                     <text>
                        <br/>
                        <paragraph>Hemodialysis removes cefdinir from the body. In patients maintained on chronic hemodialysis, the recommended initial dosage regimen is a 300 mg or 7 mg/kg dose every other day. At the conclusion of each hemodialysis session, 300 mg (or 7 mg/kg) should be given. Subsequent doses (300 mg or 7 mg/kg) are then administered every other day.</paragraph>
                     </text>
                     <effectiveTime value="20240223"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="313eec64-4e1f-7783-e063-6394a90a400c"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Cefdinir Capsules USP, 300 mg are lavender opaque/turquoise opaque size ‘0’ hard gelatin capsule filled with off-white to yellow powder and imprinted with ‘E99’ on turquoise opaque body with black ink.</paragraph>
                  <paragraph/>
                  <paragraph>NDC: 70518-1880-00</paragraph>
                  <paragraph>NDC: 70518-1880-01</paragraph>
                  <paragraph>PACKAGING: 20 in 1 BOTTLE PLASTIC</paragraph>
                  <paragraph>PACKAGING: 14 in 1 BOTTLE PLASTIC </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Preserve in tight, light-resistant containers.</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>Repackaged and Distributed By:</paragraph>
                  <paragraph>Remedy Repack, Inc.</paragraph>
                  <paragraph>625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762</paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20240223"/>
            </section>
         </component>
         <component>
            <section ID="Section_13">
               <id root="120ef4d6-8feb-f30d-e063-6294a90a3d9c"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>CLINICAL STUDIES</title>
               <effectiveTime value="20240223"/>
               <component>
                  <section ID="Section_13.1">
                     <id root="120ef4d6-8fec-f30d-e063-6294a90a3d9c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Community-Acquired Bacterial Pneumonia</title>
                     <text>
                        <br/>
                        <paragraph>In a controlled, double-blind study in adults and adolescents conducted in the U.S., cefdinir BID was compared with cefaclor 500 mg TID. Using strict evaluability and microbiologic/clinical response criteria 6 to 14 days posttherapy, the following clinical cure rates, presumptive microbiologic eradication rates, and statistical outcomes were obtained:</paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="536">
                           <caption>U.S. Community-Acquired Pneumonia Study Cefdinir vs Cefaclor</caption>
                           <col width="30.4672897196262%"/>
                           <col width="21.6822429906542%"/>
                           <col width="24.6728971962617%"/>
                           <col width="23.1775700934579%"/>
                           <thead>
                              <tr>
                                 <th align="left" styleCode="Lrule Rrule Toprule"/>
                                 <th align="center" styleCode="Lrule Rrule Toprule">Cefdinir BID</th>
                                 <th align="center" styleCode="Lrule Rrule Toprule">Cefaclor TID</th>
                                 <th align="center" styleCode="Lrule Rrule Toprule">Outcome</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">   Clinical Cure Rates</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">150/187 (80%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">147/186 (79%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">Cefdinir equivalent to control 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">   Eradication Rates</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">  
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">  
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">  
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">   Overall 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">177/195 (91%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">184/200 (92%) 
     <br/>
                                 </td>
                                 <td rowspan="5" align="center" styleCode="Rrule" valign="middle">Cefdinir equivalent to control 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="italics">   S. pneumoniae</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">31/31 (100%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">35/35 (100%) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="italics">   H. influenzae</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">55/65 (85%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">60/72 (83%) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="italics">   M. catarrhalis</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">10/10 (100%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">11/11 (100%) 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="italics">   H. parainfluenzae</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">81/89 (91%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">78/82 (95%) 
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>In a second controlled, investigator-blind study in adults and adolescents conducted primarily in Europe, cefdinir BID was compared with amoxicillin/clavulanate 500/125 mg TID. Using strict evaluability and clinical response criteria 6 to 14 days posttherapy, the following clinical cure rates, presumptive microbiologic eradication rates, and statistical outcomes were obtained:</paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="775.39">
                           <caption>European Community-Acquired Pneumonia Study Cefdinir vs Amoxicillin/Clavulanate</caption>
                           <col width="27.958833619211%"/>
                           <col width="22.6415094339623%"/>
                           <col width="22.6415094339623%"/>
                           <col width="26.7581475128645%"/>
                           <thead>
                              <tr>
                                 <th align="left" styleCode="Lrule Rrule Toprule"/>
                                 <th align="center" styleCode="Lrule Rrule Toprule">Cefdinir BID</th>
                                 <th align="center" styleCode="Lrule Rrule Toprule">Amoxicillin/Clavulanate 
     <br/>  TID
    </th>
                                 <th align="center" styleCode="Lrule Rrule Toprule">Outcome</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">   Clinical Cure Rates</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">83/104 (80%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">86/97(89%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">Cefdinir not equivalent to control 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">   Eradication Rates</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">  
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">  
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">  
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">   Overall 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">85/96 (89%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">84/90 (93%) 
     <br/>
                                 </td>
                                 <td rowspan="5" align="center" styleCode="Rrule" valign="middle">Cefdinir equivalent to control 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="italics">   S. pneumoniae</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">42/44 (95%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">43/44 (98%) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="italics">   H. influenzae</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">26/35 (74%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">21/26 (81%) 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="italics">   M. catarrhalis</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">6/6 (100%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">8/8 (100%) 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="italics">   H. parainfluenzae</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">11/11 (100%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">12/12 (100%) 
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240223"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_13.2">
                     <id root="120ef4d6-8fed-f30d-e063-6294a90a3d9c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Streptococcal Pharyngitis/Tonsillitis</title>
                     <text>
                        <br/>
                        <paragraph>In four controlled studies conducted in the United States, cefdinir was compared with 10 days of penicillin in adult, adolescent, and pediatric patients. Two studies (one in adults and adolescents, the other in pediatric patients) compared 10 days of cefdinir QD or BID to penicillin 250 mg or 10 mg/kg QID. Using strict evaluability and microbiologic/clinical response criteria 5 to 10 days posttherapy, the following clinical cure rates, microbiologic eradication rates, and statistical outcomes were obtained:</paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="586">
                           <caption>Pharyngitis/Tonsillitis Studies Cefdinir (10 days) vs Penicillin (10 days)</caption>
                           <col width="16.7521367521367%"/>
                           <col width="19.3162393162393%"/>
                           <col width="14.3589743589744%"/>
                           <col width="12.6495726495726%"/>
                           <col width="14.3589743589744%"/>
                           <col width="22.5641025641026%"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule">Study</th>
                                 <th align="center" styleCode="Lrule Rrule Toprule">Efficacy Parameter</th>
                                 <th align="center" styleCode="Lrule Rrule Toprule">Cefdinir QD</th>
                                 <th align="center" styleCode="Lrule Rrule Toprule">Cefdinir BID</th>
                                 <th align="center" styleCode="Lrule Rrule Toprule">Penicillin QID</th>
                                 <th align="center" styleCode="Lrule Rrule Toprule">Outcome</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td rowspan="2" styleCode="Lrule Rrule" valign="top">   Adults/Adolescents 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">Eradication of
    
     <content styleCode="italics">S. pyogenes</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">192/210 (91%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">199/217 (92%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">181/217 (83%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">Cefdinir superior to control 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="middle">Clinical Cure Rates 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">199/210 (95%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">209/217 (96%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">193/217 (89%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">Cefdinir superior to control 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td rowspan="2" styleCode="Lrule Rrule" valign="top">   Pediatric Patients 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">Eradication of
    
     <content styleCode="italics">S. pyogenes</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">215/228 (94%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">214/227 (94%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">159/227 (70%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">Cefdinir superior to control 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Lrule Rrule" valign="middle">Clinical Cure Rates 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">222/228 (97%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">218/227 (96%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">196/227 (86%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">Cefdinir superior to control 
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>Two studies (one in adults and adolescents, the other in pediatric patients) compared 5 days of cefdinir BID to 10 days of penicillin 250 mg or 10 mg/kg QID. Using strict evaluability and microbiologic/clinical response criteria 4 to 10 days posttherapy, the following clinical cure rates, microbiologic eradication rates, and statistical outcomes were obtained:</paragraph>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0" width="752.78">
                           <caption>Pharyngitis/Tonsillitis Studies Cefdinir (5 days) vs Penicillin (10 days)</caption>
                           <col width="23.1448763250883%"/>
                           <col width="19.9646643109541%"/>
                           <col width="14.4876325088339%"/>
                           <col width="17.6678445229682%"/>
                           <col width="24.7349823321555%"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule Toprule">Study</th>
                                 <th align="center" styleCode="Lrule Rrule Toprule">Efficacy Parameter</th>
                                 <th align="center" styleCode="Lrule Rrule Toprule">Cefdinir BID</th>
                                 <th align="center" styleCode="Lrule Rrule Toprule">Penicillin QID</th>
                                 <th align="center" styleCode="Lrule Rrule Toprule">Outcome</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td rowspan="2" styleCode="Lrule Rrule" valign="top">   Adults/Adolescents 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">Eradication of
    
     <content styleCode="italics">S. pyogenes</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">193/218 (89%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">176/214 (82%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">Cefdinir equivalent to control 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="middle">Clinical Cure Rates 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">194/218 (89%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">181/214 (85%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">Cefdinir equivalent to control 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td rowspan="2" styleCode="Lrule Rrule" valign="top">   Pediatric Patients 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">Eradication of
    
     <content styleCode="italics">S. pyogenes</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">176/196 (90%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">135/193 (70%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">Cefdinir superior to control 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Lrule Rrule" valign="middle">Clinical Cure Rates 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">179/196 (91%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">173/193 (90%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">Cefdinir equivalent to control 
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240223"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_14">
               <id root="120f24c5-40dc-5fba-e063-6394a90a7b60"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>REFERENCES</title>
               <text>
                  <paragraph/>
                  <list listType="ordered" styleCode="Arabic">
                     <item>Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.</item>
                     <item>Schwartz GJ, Haycock GB, Edelmann CM, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976;58:259-63.</item>
                     <item>Schwartz GJ, Feld LG, Langford DJ. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatrics 1984;104:849-54.</item>
                  </list>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="italics">Maalox 
   <sup>®</sup>TC is a registered trademark of Novartis Consumer Health, Inc. 
  </content>
                  </paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="italics">Clinitest</content>
                     <content styleCode="italics">
                        <sup>®</sup>is a registered trademark of Miles, Inc. 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Clinistix</content>
                     <content styleCode="italics">
                        <sup>®</sup>is a registered trademark of Bayer Corporation. 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Tes-Tape</content>
                     <content styleCode="italics">
                        <sup>®</sup>is a registered trademark of Lilly Inc. 
  </content>
                     <br/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Repackaged and Distributed By:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Remedy Repack, Inc.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762</content>
                  </paragraph>
               </text>
               <effectiveTime value="20240223"/>
            </section>
         </component>
         <component>
            <section ID="id_link_313ef751-de2d-cc1d-e063-6294a90a0fb8">
               <id root="313ef751-de2c-cc1d-e063-6294a90a0fb8"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>DRUG: Cefdinir</paragraph>
                  <paragraph>GENERIC: Cefdinir</paragraph>
                  <paragraph>DOSAGE: CAPSULE</paragraph>
                  <paragraph>ADMINSTRATION: ORAL</paragraph>
                  <paragraph>NDC: 70518-1880-0</paragraph>
                  <paragraph>NDC: 70518-1880-1</paragraph>
                  <paragraph>COLOR: purple</paragraph>
                  <paragraph>SHAPE: CAPSULE</paragraph>
                  <paragraph>SCORE: No score</paragraph>
                  <paragraph>SIZE: 21 mm</paragraph>
                  <paragraph>IMPRINT: E99</paragraph>
                  <paragraph>PACKAGING: 20 in 1 BOTTLE, PLASTIC</paragraph>
                  <paragraph>PACKAGING: 14 in 1 BOTTLE, PLASTIC</paragraph>
                  <paragraph>ACTIVE INGREDIENT(S):</paragraph>
                  <list listType="unordered">
                     <item>CEFDINIR 300mg in 1</item>
                  </list>
                  <paragraph>INACTIVE INGREDIENT(S):</paragraph>
                  <list listType="unordered">
                     <item>CARBOXYMETHYLCELLULOSE CALCIUM</item>
                     <item>SILICON DIOXIDE</item>
                     <item>MAGNESIUM STEARATE</item>
                     <item>FD&amp;C BLUE NO. 1</item>
                     <item>D&amp;C RED NO. 28</item>
                     <item>TITANIUM DIOXIDE</item>
                     <item>GELATIN, UNSPECIFIED</item>
                     <item>SODIUM LAURYL SULFATE</item>
                     <item>FERROSOFERRIC OXIDE</item>
                     <item>SHELLAC</item>
                  </list>
                  <paragraph>
                     <renderMultiMedia referencedObject="Remedy_Label"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_313ef4f5-1cfc-a9d4-e063-6294a90aed0a"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240223"/>
               <component>
                  <observationMedia ID="Remedy_Label">
                     <text>Remedy_Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Remedy_Label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="img_313ef4f5-1cfc-a9d4-e063-6294a90aed0a">
                     <text>MM2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Cefdinir 300mg_70518-1880-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>